We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Seeking Clues to Illumina (ILMN) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
Read MoreHide Full Article
Wall Street analysts forecast that Illumina (ILMN - Free Report) will report quarterly earnings of $0.13 per share in its upcoming release, pointing to a year-over-year decline of 61.8%. It is anticipated that revenues will amount to $1.13 billion, exhibiting an increase of 1.5% compared to the year-ago quarter.
Over the last 30 days, there has been a downward revision of 4.7% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Illumina metrics that are commonly monitored and projected by Wall Street analysts.
The consensus estimate for 'Revenue- Service and other revenue' stands at $175.45 million. The estimate indicates a change of +15.4% from the prior-year quarter.
The average prediction of analysts places 'Revenue- Microarrays- Consumables' at $76.43 million. The estimate indicates a change of +0.6% from the prior-year quarter.
The combined assessment of analysts suggests that 'Revenue- Microarrays- Instruments' will likely reach $4.83 million. The estimate indicates a change of -3.4% from the prior-year quarter.
Analysts' assessment points toward 'Revenue- Sequencing- Instruments' reaching $175.78 million. The estimate points to a change of +8.5% from the year-ago quarter.
Analysts expect 'Revenue- Sequencing- Consumables' to come in at $690.38 million. The estimate suggests a change of -4.8% year over year.
The consensus among analysts is that 'Revenue- Product revenue' will reach $945.31 million. The estimate indicates a year-over-year change of -1.8%.
Analysts forecast 'Revenue- Sequencing- Total' to reach $1.05 billion. The estimate points to a change of +4.2% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenue- Sequencing- Service & Other' should arrive at $158.11 million. The estimate points to a change of +28.5% from the year-ago quarter.
According to the collective judgment of analysts, 'Revenue- Microarrays- Total' should come in at $107.66 million. The estimate points to a change of +7.7% from the year-ago quarter.
It is projected by analysts that the 'Revenue- Microarrays- Service & Other' will reach $23.53 million. The estimate suggests a change of +23.8% year over year.
Analysts predict that the 'Geographic Revenue- United States' will reach $616.89 million. The estimate indicates a year-over-year change of +4.2%.
The collective assessment of analysts points to an estimated 'Geographic Revenue- Greater China' of $118.03 million. The estimate indicates a year-over-year change of -11.3%.
Illumina shares have witnessed a change of -16.5% in the past month, in contrast to the Zacks S&P 500 composite's +3.1% move. With a Zacks Rank #3 (Hold), ILMN is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Seeking Clues to Illumina (ILMN) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
Wall Street analysts forecast that Illumina (ILMN - Free Report) will report quarterly earnings of $0.13 per share in its upcoming release, pointing to a year-over-year decline of 61.8%. It is anticipated that revenues will amount to $1.13 billion, exhibiting an increase of 1.5% compared to the year-ago quarter.
Over the last 30 days, there has been a downward revision of 4.7% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Illumina metrics that are commonly monitored and projected by Wall Street analysts.
The consensus estimate for 'Revenue- Service and other revenue' stands at $175.45 million. The estimate indicates a change of +15.4% from the prior-year quarter.
The average prediction of analysts places 'Revenue- Microarrays- Consumables' at $76.43 million. The estimate indicates a change of +0.6% from the prior-year quarter.
The combined assessment of analysts suggests that 'Revenue- Microarrays- Instruments' will likely reach $4.83 million. The estimate indicates a change of -3.4% from the prior-year quarter.
Analysts' assessment points toward 'Revenue- Sequencing- Instruments' reaching $175.78 million. The estimate points to a change of +8.5% from the year-ago quarter.
Analysts expect 'Revenue- Sequencing- Consumables' to come in at $690.38 million. The estimate suggests a change of -4.8% year over year.
The consensus among analysts is that 'Revenue- Product revenue' will reach $945.31 million. The estimate indicates a year-over-year change of -1.8%.
Analysts forecast 'Revenue- Sequencing- Total' to reach $1.05 billion. The estimate points to a change of +4.2% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenue- Sequencing- Service & Other' should arrive at $158.11 million. The estimate points to a change of +28.5% from the year-ago quarter.
According to the collective judgment of analysts, 'Revenue- Microarrays- Total' should come in at $107.66 million. The estimate points to a change of +7.7% from the year-ago quarter.
It is projected by analysts that the 'Revenue- Microarrays- Service & Other' will reach $23.53 million. The estimate suggests a change of +23.8% year over year.
Analysts predict that the 'Geographic Revenue- United States' will reach $616.89 million. The estimate indicates a year-over-year change of +4.2%.
The collective assessment of analysts points to an estimated 'Geographic Revenue- Greater China' of $118.03 million. The estimate indicates a year-over-year change of -11.3%.
View all Key Company Metrics for Illumina here>>>
Illumina shares have witnessed a change of -16.5% in the past month, in contrast to the Zacks S&P 500 composite's +3.1% move. With a Zacks Rank #3 (Hold), ILMN is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>